ZEALAND PHARMA/S (NASDAQ:ZEAL) hit a new 52-week high on Tuesday . The company traded as high as $20.92 and last traded at $20.92, with a volume of 2600 shares changing hands. The stock had previously closed at $20.26.

ZEAL has been the topic of a number of analyst reports. TheStreet upgraded shares of ZEALAND PHARMA/S from a “d+” rating to a “c-” rating in a report on Tuesday, January 22nd. Needham & Company LLC restated a “buy” rating and issued a $29.00 price objective on shares of ZEALAND PHARMA/S in a report on Thursday, March 7th. ValuEngine upgraded shares of ZEALAND PHARMA/S from a “sell” rating to a “hold” rating in a report on Friday, March 15th. Finally, Zacks Investment Research lowered shares of ZEALAND PHARMA/S from a “buy” rating to a “hold” rating and set a $21.00 price objective on the stock. in a report on Saturday, April 13th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $26.00.

The firm has a market cap of $611.12 million, a price-to-earnings ratio of 6.98 and a beta of 2.40.

ZEALAND PHARMA/S (NASDAQ:ZEAL) last posted its earnings results on Thursday, May 16th. The company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.45). As a group, equities research analysts expect that ZEALAND PHARMA/S will post -1.68 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in ZEALAND PHARMA/S stock. Jane Street Group LLC bought a new stake in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 25,285 shares of the company’s stock, valued at approximately $320,000. Jane Street Group LLC owned 0.08% of ZEALAND PHARMA/S as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 9.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ZEALAND PHARMA/S (ZEAL) Sets New 1-Year High at $20.92” was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/zealand-pharma-s-zeal-sets-new-1-year-high-at-20-92/3017826.html.

About ZEALAND PHARMA/S (NASDAQ:ZEAL)

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Featured Story: Purposes and Functions of the Federal Reserve

Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.